# P8 and p12 had dominant mutations in 3CLpro. Antiviral testing with p13 stock indicated strong resistance toALG-097161and cross-resistance to both nirmatrelvir and 
# PF-00835231. EC50 increased 63x for ALG-097161. EC50 increased 51x for Nirmatrelvir. EC50 increased 23x for PF-00835231. EC50 increased 2.1x for GS-441524. Tested   
# using FRET assay.
# Jochmans et al. (2022) http://doi.org/10.1101/2022.06.07.495116
L167F

# P8 and p12 had dominant mutations in 3CLpro. Antiviral testing with p13 stock indicated strong resistance toALG-097161and cross-resistance to  both nirmatrelvir and 
# PF-00835231. EC50 increased 63x for ALG-097161. EC50 increased 51x for Nirmatrelvir. EC50 increased 23x for PF-00835231. EC50 increased 2.1x for GS-441524. Tested   
# using FRET assay.
# Jochmans et al. (2022) http://doi.org/10.1101/2022.06.07.495116
L50F

# P8 and p12 had dominant mutations in 3CLpro. Antiviral testing with p13 stock indicated strong resistance toALG-097161and cross-resistance to  both nirmatrelvir and 
# PF-00835231. EC50 increased 63x for ALG-097161. EC50 increased 51x for Nirmatrelvir. EC50 increased 23x for PF-00835231. EC50 increased 2.1x for GS-441524. Tested   
# using FRET assay.
# Jochmans et al. (2022) http://doi.org/10.1101/2022.06.07.495116
E166A

# This mutation renders 3CL enzymatically inactive, as determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H41M

# This mutation renders 3CL enzymatically inactive, as determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H41T

# This mutation renders 3CL enzymatically inactive, as determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H41Y

# This mutation renders 3CL enzymatically inactive, as determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H163W

# This mutation causes a 38.0x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
S144M

# This mutation causes a 19.2x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
S144F

# This mutation causes a 20.5x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
S144A

# This mutation causes a 20.4x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
S144G

# This mutation causes a 21.3x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
S144Y

# This mutation causes a 29.9x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
M165T

# This mutation causes a 11.7x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
E166Q

# This mutation causes a 42.4x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H172Q

# This mutation causes a 42.5x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H172F

# This mutation causes a 32.9x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
Q192T

# This mutation causes a 46.7x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
Q192S

# This mutation causes a 22.2x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki.  Enzymatic activity 
# remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
Q192V

# This mutation combination causes a 281.1x increase in resistance to Nirmatrelvir, the protease inhibitor component of paxlovid, as measured by Ki. 
# Enzymatic activity remains comparable to wild-type (kcat/Km <10-fold change).  Both constants were determined by FRET assay, and resistance was confirmed 
# by thermal shift binding assay.
# Hu et al. (2022) http://doi.org/10.1101/2022.06.28.497978
H172Y;Q189E

# In a escape mutation generation experiment using protease inhibitor boceprevir, all four independent experiments
# revealed this mutation combination. Two of the samples had up to 4.7x resistance to boceprevir as measured by EC50 in Vero E6 cells.
# This resistence was NOT recapitulated in a subsequent confirmatory bacterial artificial chromosome (BAC) clone experiment.
# Zhou et al. (2022) http://doi.org/10.1101/2022.06.06.494921
# In a escape mutation generation experiment using protease inhibitor nirmatrelvir, samples previously escaping boceprevir with this 
# mutation combination had up to 6.8x resistance to nirmatrelvir as measured by EC50 in Vero E6 cells.
# This resistence was NOT recapitulated in a subsequent confirmatory bacterial artificial chromosome (BAC) clone experiment.
# Remdesivir effectiveness was not significantly affected by this mutation combination, suggesting that ciombined treatment would be
# less likely to induce resistance.
# Zhou et al. (2022) http://doi.org/10.1101/2022.06.06.494921
L50F;A173V

# In a escape mutation generation experiment using protease inhibitor nirmatrelvir, one of two independent experiments
# generated this mutation combination. It provides 5.9x resistance to nirmatrelvir as measured by EC50 in Vero E6 cells.
# Remdesivir effectiveness was not significantly affected by this mutation combination, suggesting that ciombined treatment would be
# less likely to induce resistance.
# Zhou et al. (2022) http://doi.org/10.1101/2022.06.06.494921
T21I;T304I

# In a escape mutation generation experiment using protease inhibitor nirmatrelvir, one of two independent experiments
# generated this mutation combination. It provides 175x resistance to nirmatrelvir as measured by EC50 in Vero E6 cells.
# The significance of these putative resistance substitutions was confirmed by reverse genetics using a bacterial artificial 
# chromosome (BAC) clone, which displayed ~80x resistance.
# Remdesivir effectiveness was not significantly affected by this mutation combination, suggesting that ciombined treatment would be
# less likely to induce resistance.
# Zhou et al. (2022) http://doi.org/10.1101/2022.06.06.494921
L50F;E166V 

# [Data suggests that observed A173V and E166V mutations have a fitness cost, and that L50F is compensatory.]
# Zhou et al. (2022) http://doi.org/10.1101/2022.06.06.494921
L50F

# This mutation (found in the lambda VOC) causes a 4.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. However, this did not impact the susceptability to Nirmatrelvir.
# FDA (2021) https://www.fda.gov/media/155050/download
G15S

# This mutation causes a 3.5x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
T135I

# This mutation causes a 91.9x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
S144A

# This mutation causes a 6.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
H164N

# This mutation causes a 233x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
H172Y

# This mutation causes a 65.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
Q189K

# This mutation causes a 3.7x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
D248E

# This mutation causes a 23.6x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
 Y54A

# This mutation causes a 39x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
F140A

# This mutation causes a 33.4x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
E166A 

# This mutation in mouse hepatitis virus subsitution residue emerges in cell culture resistance assay. This resulted in 4-5x fold higher EC50 values.
# FDA (2021) https://www.fda.gov/media/155050/download
S144A;E55L

# This causes a 91.9x drop in the binding of Nirmatrelvir, the protease inhibitor component of paxlovid. 
# FDA (2021) https://www.fda.gov/media/155050/download
S144A
